The listings featured on this site are from companies from which this site receives compensation. This influences where, how and in what order such listings appear on this site. Advertising Disclosure

Compare Tirzepatide Weight Loss Injections 2026

Compare telehealth programs prescribing tirzepatide — the dual-action GLP-1/GIP medication — with clinician review, clear pricing, and ongoing treatment support.

Last Updated: Jun 2026

What’s on this page?

  1. Top tirzepatide programs of 2026 (above)
  2. What tirzepatide is
  3. What SURMOUNT-1 showed
  4. Tirzepatide vs. semaglutide
  5. How dosing and titration work
  6. Safety information worth reading first
  7. Choosing a tirzepatide program

What is tirzepatide?

Tirzepatide is the first weight-management medication that activates two gut-hormone receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). According to the FDA, this dual action reduces appetite and food intake.

The FDA approved tirzepatide for chronic weight management in November 2023 under the brand name Zepbound, for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. The same molecule was already approved as Mounjaro for type 2 diabetes — same ingredient, different indication.

What did SURMOUNT-1 show?

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight, without diabetes, across 119 sites. At week 72, average body-weight reductions were 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg — versus 3.1% for placebo. Nine in ten participants on the highest dose lost at least 5% of their body weight.

Three-year follow-up data added two important findings: weight reductions were largely sustained while participants stayed on treatment, and weight regain was observed after the 17-week off-treatment period. Translation for real life: tirzepatide is a treatment you plan around, not a one-time fix.

Tirzepatide vs. semaglutide — how do they compare?

Both are once-weekly injections approved for chronic weight management, and both were studied with lifestyle intervention. The headline trial numbers differ: semaglutide 2.4 mg averaged a 14.9% reduction at 68 weeks in STEP 1, while tirzepatide's higher doses averaged roughly 20% at 72 weeks in SURMOUNT-1.

Cross-trial comparisons are imperfect — different participants, different protocols — and reviewers note that head-to-head conclusions need dedicated studies. The practical takeaway: both are credible options, and the right one depends on your medical history, insurance coverage, side-effect tolerance, and what your clinician recommends.

How do dosing and titration work?

Zepbound is injected under the skin once weekly. Per the FDA, treatment starts low and the dose increases over 4 to 20 weeks to reach a target of 5 mg, 10 mg, or 15 mg weekly — gradual on purpose, because the most common side effects are gastrointestinal and tend to cluster during dose escalation.

In SURMOUNT-1, serious adverse events were no more common on tirzepatide than placebo, but between 4% and 7% of participants stopped treatment because of side effects. A program that makes it easy to reach your care team during titration is worth more than a small price difference.

Safety information worth reading first

The FDA's approval announcement lists warnings you should know before an online visit: tirzepatide should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2, it has not been studied in people with a history of pancreatitis or severe gastrointestinal disease, and it must not be combined with other GLP-1 medications.

Common side effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, and reflux. None of this replaces a conversation with a licensed clinician — it is the baseline you should expect a good program to cover with you.

How should you choose a tirzepatide program?

Start from the chart above, then compare on the details that shape your experience: whether the program offers brand-name Zepbound or a compounded alternative, what the monthly price includes at each dose level, how refills are timed so you do not run out mid-titration, and whether clinician messaging is included after the first prescription.

Cash prices often rise as doses increase — ask for the 10 mg and 15 mg pricing up front, not just the starting-dose teaser. And if a program advertises compounded tirzepatide, confirm the pharmacy source and oversight before paying.

Ready to compare tirzepatide programs?

Shortlist from the chart, open the company reviews, and confirm total cost across doses, pharmacy source, and clinician access before starting an online visit.

Sources used for medical context

  1. FDA Zepbound approval announcement (2023) for indication, mechanism, titration, and safety warnings.
  2. SURMOUNT-1 trial summary (ACC) for trial design, outcomes, and three-year follow-up.
  3. STEP 1 trial for the semaglutide comparison context.

How We Rank

Learn more about how comparetreatments.com rankings are determined.

Frequently Asked Questions (FAQ)

Tirzepatide is the active ingredient in both. Zepbound is the brand the FDA approved for chronic weight management; Mounjaro is approved for blood sugar control in type 2 diabetes. The FDA notes they should not be used together, and a clinician determines which is appropriate.
In SURMOUNT-1, average body-weight reductions at 72 weeks were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% for placebo, alongside lifestyle intervention. Those are supervised-trial averages — individual results depend on dose, tolerance, and adherence.
Per the FDA, people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not use it, and it has not been studied in people with a pancreatitis history or severe gastrointestinal disease. Pregnancy also rules it out. Your clinician reviews the full list.
The FDA lists nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, and reflux. In SURMOUNT-1 these were mostly mild-to-moderate and clustered during dose escalation. Persistent or severe symptoms warrant contacting your care team.
SURMOUNT-1's extended follow-up observed weight regain in former tirzepatide groups after a 17-week off-treatment period. That makes a maintenance plan — lifestyle structure plus a clinician conversation about duration — part of the decision, not an afterthought.